Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Resear... (XMT-1107 inhibited human MetAP2 in vitro...)

HOME >> MEDICINE >> NEWS

Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting

Date:4/19/2009

XMT-1107 inhibited human MetAP2 in vitro, was highly active in human umbilical vein endothelial cell (HUVEC) proliferation assays, and showed anti-angiogenesis activity in vivo in the Matrigel plug assay. Additionally, XMT-1107 was active in a number of syngeneic and xenograft tumor models. The enhanced antiangiogenic and in vivo anti-tumor activity of XMT-1107 compared to its in vivo release product XMT-1191 clearly demonstrated the benefit of conjugating XMT-1191 to Fleximer(R) and supports the potential clinical utility of XMT-1107 as an anti-cancer agent.

"Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat"

By Alex Yurkovetskiy, Dana L. Shkolny, Laura C. Akullian, Mao Yin, Laraine L. Meyers, Robert J. Fram, Timothy B. Lowinger.

This study evaluated the pharmacokinetics (PK) of XMT-1107 and its conjugate release product, XMT-1191, in rats. The XMT-1107 conjugate extended exposure to its corresponding drug release product, XMT-1191, while significantly reducing (> 500 fold) maximum XMT-1191 plasma levels (Cmax).

The data suggest that the slow rate of release of XMT-1191 from the polymer conjugate XMT-1107 provided a low but consistent exposure to the highly active XMT-1191 small molecule, providing an apparent half life of 22 hours compared with a half life of less than five minutes with free XMT-1191 administration. The data are consistent with the significantly higher in vivo activity seen for XMT-1107 relative to XMT-1191 in xenograft activity reported in a separate poster.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary technology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. Mersana's lead compound, XMT-1001, is currently in Phase I trials in cancer patients. Mersana's secon
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Secondhand Smoke Quickly Affects Blood Vessels
2. Every 30 Seconds an African Child Dies from Malaria; Education Key to Prevention
3. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
4. Valensa Completes Second Expansion of Astaxanthin Capacity
5. Success of Colorful School Supply Collection Inspired by Leukemia Patient Kicks off Second Year
6. Metro Parents Second Annual Living With Autism Workshop Features Local Experts Who Are Intimately Involved in Improving the Lives of These Special Children
7. Equinox Fitness Clubs Continues National Expansion with the Opening of its Second Boston Location
8. Second European Radiosurgery Workshop Yields Record Attendance
9. Secondhand Smoke Affecting Millions of New Yorkers
10. Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance
11. MoleSafe USA Opens Second Location in Albuquerque, New Mexico

Post Your Comments:

(Date:12/15/2009)... BALTIMORE, Dec. 15 SUMMARY: ... the Patient Protection and Affordable Care Act that ... by allowing for the safe and legal importation ... amendment, endorsed by AARP and sponsored by Senators ... improved competition and helped to bring down the ...

(Date:12/15/2009)... of coal for lying about taxes in the healthcare bill ... Baucus has earned a place under the "Naughty" column on ... after being caught telling a brazen lie on the ... healthcare bill would not raise taxes. ,, Speaking on ... " I have also heard ...

(Date:12/15/2009)... of leptin associated with lower dementia risk, research finds ... levels of leptin, a hormone that regulates appetite, may ... in 10 or 15 years this may be one ... risk of Alzheimer,s disease," said senior study author Dr. ... University School of Medicine. "Or it may be one ...

(Date:12/15/2009)... education program will train advocates to be leaders ... Project developed with support from experts in online ... ,, WASHINGTON, Dec. 15 ... are accepting applications for the first-ever "Malaria Griots" ... and educate participants to become leaders in the ...

(Date:12/15/2009)... The following are the remarks by ... criminal division, at the Medicare Fraud Strike Force ... thank you for the enormous effort everyone at ... ,, Together, our Departments have and will continue ... made tremendous progress in fighting Medicare fraud in ...

Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2 Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3 Health News:Fat Hormone May Protect Against Alzheimer's 2 Health News:Fat Hormone May Protect Against Alzheimer's 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 2 Health News:ONE and Malaria No More Launch 'Malaria Griots' 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 4 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3

[0] AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices [0] ATR: Baucus Earns Place on 2009 "Naughty" List [0] Fat Hormone May Protect Against Alzheimer's [0] ONE and Malaria No More Launch 'Malaria Griots'[1] Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference

... (Washington) "The benefits of widespread adoption of interoperable ... to a higher standard of quality in the U.S. ... House Ways and Means Committee subcommittee on Health today. ... their patients will be left behind the technological curve." ...

... Immunochemist Mark C. Swanson got,leading scientists and ... a bright future for natural rubber latex (NRL) ... of Vytex(TM),NRL from Vystar Corporation. This commercially available ... as raw material while,preserving desirable NRL properties in ...

... research facility is planned to enable unprecedented understanding of ... human behaviour. The 28.5 million funding comes from ... and Skills (DIUS), and will be used for the ... a collaboration between the Economic and Social Research Council ...

... annual Retail Business Conference, company launches exclusive brand, ... outbound ... technology, ORLANDO, Fla., July 24 As consumerism, ... the way health care is delivered, Cardinal Health today ...

... The board of,directors for Hillenbrand, Inc. (NYSE: ... million of the company,s outstanding common shares. Purchases,will be ... or in privately,negotiated transactions, and will be funded from ... decision to implement a share repurchase program for our,new ...

... $0.38 in ... Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding $0.05 in ... from the 2003 spin-off ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

ACP says Medicare should increase payments for physicians that use HIT to improve quality Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing £28.5M investment for groundbreaking new research facility Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance

(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...

(Date:12/15/2009)... Dec. 15 Dynatronics Corporation ... a preferred vendor agreement to provide therapy equipment ... (PTP), a nationwide network of physical, occupational and ... working with Preferred Therapy Providers," said Larry K. ... at Dynatronics. "Their vast network of 1,100 clinics ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... of the competitive environment is unquestionably ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...

Breaking Medicine Technology:Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3 Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2 Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 1 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 2 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 3 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 4 Tickets On Sale Now 3A Bridge to Hope All Day Music Festival to Feature Top Artists Gourmet Food Art Show Saturday September 26th at Fort Masons G 4880 5 Dallas Physician Elected to Lead International Organ Transplant Society 55053 1 Dallas Physician Elected to Lead International Organ Transplant Society 55053 2 Dallas Physician Elected to Lead International Organ Transplant Society 55053 3 Gene Linked to Inherited Kidney Disease Found 55049 1

[0] Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study [0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.[0] Reportlinker Adds Top Ten World's Leading Orthopedics Companies

... PARIS, June 30 Five years after the ... disease causing accelerated and,premature ageing, a team of ... University of Oviedo - and Nicolas Levy and ... treatment,for the disease, using mice. This treatment, combining ...

... LONDON and PHILADELPHIA, June 30 ,GlaxoSmithKline (NYSE: GSK ... the U.S. Food and Drug Administration (FDA) for approval,of ... has submitted its response to questions raised by the ... In addition, given,that final data from GSK,s Phase III ...

Other Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2 GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 2 GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval 3

Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval

... improved OrthoWedge® Healing Shoe offers the most ... forefoot while allowing patients to maintain their ... wedge, an even larger portion of the ... the metatarsal heads and toes to heal ...

Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....

... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...

... is a given with our High Beam TriLens ... and remarkably brilliant 11.5 cm spot at a ... its class. , ,To achieve this unequaled performance ... with three of the finest Mag-Fluoride coated lenses ...

Medicine Products:

OrthoWedge Healing Shoes Polycast Cast Boot Gliadin IgG Kit High Beam TriLens Classic and Sport

Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Resear...(XMT-1107 inhibited human MetAP2 in vitro...),Health